Your session is about to expire
← Back to Search
Radiation Therapy
MR-Guided Radiotherapy for Prostate Cancer (MRL-Boost Trial)
N/A
Recruiting
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
18 years of age or older
Planned for EBRT (+/- ADT)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 5-year follow-up
Awards & highlights
MRL-Boost Trial Summary
This trial is testing a new treatment for prostate cancer that involves MR-guided radiotherapy. 40 patients will be recruited and monitored for up to 5 years.
Who is the study for?
This trial is for men with localized prostate cancer confirmed by tissue analysis and MRI, who are categorized as low to high-risk but ideally have only one high-risk factor. They must be planning external beam radiation therapy (possibly with hormone therapy), able to perform daily activities (ECOG 0 or 1), at least 18 years old, and can consent to the study. Men with severe bowel diseases, claustrophobia, metastases, certain genetic conditions or prior pelvic radiotherapy cannot join.Check my eligibility
What is being tested?
The study tests if giving an MR-guided radiotherapy boost directly to the tumor visible on MRI before or after whole gland radiation improves outcomes in prostate cancer patients. It's a single-arm feasibility study following participants for up to five years post-treatment.See study design
What are the potential side effects?
While not explicitly listed here, potential side effects of MR-guided radiotherapy may include skin irritation at the treatment site, fatigue, urinary issues like increased frequency or discomfort during urination, and bowel problems such as diarrhea.
MRL-Boost Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
I am scheduled for external beam radiation therapy, with or without hormone therapy.
Select...
My prostate cancer diagnosis was confirmed through a tissue examination.
Select...
My prostate cancer is high-risk with one of the following: a stage above T2, PSA over 20, or Gleason score above 7.
Select...
I am fully active or can carry out light work.
Select...
My prostate cancer is considered low risk.
Select...
My prostate cancer is at an intermediate stage with specific PSA levels or Gleason score.
Select...
My prostate cancer is confirmed to be in less than one-third of my prostate.
MRL-Boost Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to 5-year follow-up
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 5-year follow-up
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Feasibility of MR-guided Linear Acceleratorfor tumour-targeted intra-prostatic dose escalation as boost
Secondary outcome measures
Acute Toxicity
Late Toxicity
Patient-reported quality-of-life assessed by EPIC-26
MRL-Boost Trial Design
1Treatment groups
Experimental Treatment
Group I: MR-guided Tumour Boost with SBRTExperimental Treatment1 Intervention
MR-guided radiotherapy boost to MRI visible tumour
Find a Location
Who is running the clinical trial?
University Health Network, TorontoLead Sponsor
1,475 Previous Clinical Trials
485,050 Total Patients Enrolled
63 Trials studying Prostate Cancer
15,360 Patients Enrolled for Prostate Cancer
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am 18 years old or older.I am scheduled for external beam radiation therapy, with or without hormone therapy.I have Ataxia Telangiectasia or Systemic Lupus Erythematosus.I have had radiation therapy to my pelvis.My prostate cancer diagnosis was confirmed through a tissue examination.My prostate cancer is high-risk with one of the following: a stage above T2, PSA over 20, or Gleason score above 7.I am fully active or can carry out light work.My doctor confirms I have active ulcerative colitis or Crohn's Disease.My prostate cancer is considered low risk.My prostate cancer is at an intermediate stage with specific PSA levels or Gleason score.My prostate cancer is confirmed to be in less than one-third of my prostate.My doctor has found that my cancer has spread to other areas.
Research Study Groups:
This trial has the following groups:- Group 1: MR-guided Tumour Boost with SBRT
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any opportunities to enroll in this clinical research study at present?
"Contrary to popular belief, this clinical trial is not actively accepting patients. It was first listed on January 1st 2023 and the information was last revised on October 6th 2022. Despite this fact, there are still 1321 other trials seeking participants at present time."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger